{"id":2933,"date":"2020-05-14T00:00:00","date_gmt":"2020-05-14T04:00:00","guid":{"rendered":"https:\/\/icesontario.wpengine.com\/journal-articles\/identifying-drugs-with-disease%e2%80%90modifying-potential-in-parkinsons-disease-using-artificial-intelligence-and-pharmacoepidemiology\/"},"modified":"2023-06-14T19:42:16","modified_gmt":"2023-06-14T23:42:16","slug":"identifying-drugs-with-disease%e2%80%90modifying-potential-in-parkinsons-disease-using-artificial-intelligence-and-pharmacoepidemiology","status":"publish","type":"journal_article","link":"https:\/\/www.ices.on.ca\/fr\/publications\/journal-articles\/identifying-drugs-with-disease%e2%80%90modifying-potential-in-parkinsons-disease-using-artificial-intelligence-and-pharmacoepidemiology\/","title":{"rendered":"Identifying drugs with disease\u2010modifying potential in Parkinson&rsquo;s disease using artificial intelligence and pharmacoepidemiology"},"content":{"rendered":"<p><strong>Purpose <\/strong>&#x2014; The aim of the study was to assess the feasibility of an approach combining computational methods and pharmacoepidemiology to identify potentially disease&#x2010;modifying drugs in Parkinson&apos;s disease (PD).<\/p>\n<p><strong>Methods <\/strong>&#x2014; We used a two&#x2010;step approach; (a) computational method using artificial intelligence to rank 620 drugs in the Ontario Drug Benefit formulary based on their predicted ability to inhibit alpha&#x2010;synucleinaggregation, a pathogenic hallmark of PD; and (b) case&#x2010;control study using administrative databases in Ontario, Canada. Persons aged 70&#x2010;110 years with incident PD from April 2002&#x2010;March 2013. Controls were randomly selected from persons with no previous diagnosis of PD.<\/p>\n<p><strong>Results <\/strong>&#x2014; A total of 15 of the top 50 drugs were deemed feasible for pharmacoepidemiologic analysis, of which seven were significantly associated with incident PD after adjustment, with five of these seven associated with a decreased odds of PD. Methylxanthine drugs pentoxifylline (OR, 0.72; 95% CI, 0.59&#x2010;0.89) and theophylline (OR, 0.77; 95% CI, 0.66&#x2010;0.91), and the corticosteroid dexamethasone (OR, 0.72; 95% CI, 0.61&#x2010;0.85) were associated with decreased odds of PD.<\/p>\n<p><strong>Conclusions <\/strong>&#x2014; Our findings demonstrate the feasibility of this approach to focus the search for disease&#x2010;modifying drugs. Corticosteroids and methylxanthines should be further investigated as potential disease&#x2010;modifyingdrugs in PD.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Purpose &#x2014; The aim of the study was to assess the feasibility of an approach combining computational methods and pharmacoepidemiology to identify potentially disease&#x2010;modifying drugs in Parkinson&apos;s disease (PD). Methods &#x2014; We used a two&#x2010;step approach; (a) computational method using artificial intelligence to rank 620 drugs in the Ontario Drug Benefit formulary based on their [&hellip;]<\/p>\n","protected":false},"template":"","migration-helper-automated":[],"migration-manual":[],"topic":[],"migration-helper-qa-sample-set":[],"class_list":["post-2933","journal_article","type-journal_article","status-publish","hentry"],"acf":{"citation":"Maclagan LC, Visanji NP, Cheng Y, Tadrous M, Lacoste AMB, Kalia LV, Bronskill SE, Marras C. <em>Pharmacoepidemiol Drug Saf<\/em>. 2020; 29(8):864-72. Epub 2020 May 14.","source_url":"https:\/\/doi.org\/10.1002\/pds.5015","ices_scientist":[1328,1159,1108],"site":[6733],"research_program":[6740],"news_release":[],"journal_article":[],"atlas":[],"research_report":[],"infographic":[],"video":[],"downloads":null,"links":null,"sitecore_item_id":"5164855E-5B11-4C8D-911E-6E064B7E0D8C","sitecore_item_name":"Identifying-drugs-with-disease-modifying-potential-in-Parkinsons-disease-using-artificial","sitecore_field_values":"{\n  \"Title\": \"Identifying drugs with disease\u2010modifying potential in Parkinson's disease using artificial intelligence and pharmacoepidemiology\",\n  \"Short title\": \"Identifying drugs with disease\u2010modifying\",\n  \"Summary\": \"The aim of the study was to assess the feasibility of an approach combining computational methods and pharmacoepidemiology to identify potentially disease\u2010modifying drugs in Parkinson's disease.\",\n  \"Citation\": \"<p>Maclagan LC, Visanji NP, Cheng Y, Tadrous M, Lacoste AMB, Kalia LV, Bronskill SE, Marras C. <em>Pharmacoepidemiol Drug Saf<\/em>. 2020; 29(8):864-72. Epub 2020 May 14. DOI: <a href=\"https:\/\/doi.org\/10.1002\/pds.5015\" title=\"Opens external link\">https:\/\/doi.org\/10.1002\/pds.5015<\/a><\/p>\",\n  \"Abstract\": \"<p><strong>Purpose <\/strong>&mdash; The aim of the study was to assess the feasibility of an approach combining computational methods and pharmacoepidemiology to identify potentially disease\u2010modifying drugs in Parkinson's disease (PD).<\/p>n<p><strong>Methods <\/strong>&mdash; We used a two\u2010step approach; (a) computational method using artificial intelligence to rank 620 drugs in the Ontario Drug Benefit formulary based on their predicted ability to inhibit alpha\u2010synucleinaggregation, a pathogenic hallmark of PD; and (b) case\u2010control study using administrative databases in Ontario, Canada. Persons aged 70\u2010110 years with incident PD from April 2002\u2010March 2013. Controls were randomly selected from persons with no previous diagnosis of PD.<\/p>n<p><strong>Results <\/strong>&mdash; A total of 15 of the top 50 drugs were deemed feasible for pharmacoepidemiologic analysis, of which seven were significantly associated with incident PD after adjustment, with five of these seven associated with a decreased odds of PD. Methylxanthine drugs pentoxifylline (OR, 0.72; 95% CI, 0.59\u20100.89) and theophylline (OR, 0.77; 95% CI, 0.66\u20100.91), and the corticosteroid dexamethasone (OR, 0.72; 95% CI, 0.61\u20100.85) were associated with decreased odds of PD.<\/p>n<p><strong>Conclusions <\/strong>&mdash; Our findings demonstrate the feasibility of this approach to focus the search for disease\u2010modifying drugs. Corticosteroids and methylxanthines should be further investigated as potential disease\u2010modifyingdrugs in PD.<\/p>\",\n  \"Research Programs\": \"{46DF28D2-EDE8-4DF2-8CC0-87CEF464E435}\",\n  \"ICES Locations\": \"{4FCAABBA-14A5-42E6-8F33-BC6C2F1D9908}\",\n  \"ICES Scientists\": \"{6B7BCAA7-8CF8-4655-81FD-CB55616742F5}|{68FD9EE5-974B-4CED-A597-82186232FF1D}|{57F695DB-AAD1-46E5-829F-5BAB09CF881B}\",\n  \"Posted Date\": \"20200514T000000\",\n  \"Show on Publications Landing Page\": \"1\"\n}","previous_url":"https:\/\/www.ices.on.ca\/Publications\/Journal-Articles\/2020\/May\/Identifying-drugs-with-disease-modifying-potential-in-Parkinsons-disease-using-artificial"},"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.0 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>ICES | Identifying drugs with disease\u2010modifying potential in Parkinson&#039;s disease using artificial intelligence and pharmacoepidemiology<\/title>\n<meta name=\"description\" content=\"Purpose &#x2014; The aim of the study was to assess the feasibility of an approach combining computational methods and pharmacoepidemiology to identify\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.ices.on.ca\/fr\/publications\/journal-articles\/identifying-drugs-with-disease%e2%80%90modifying-potential-in-parkinsons-disease-using-artificial-intelligence-and-pharmacoepidemiology\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"ICES | Identifying drugs with disease\u2010modifying potential in Parkinson&#039;s disease using artificial intelligence and pharmacoepidemiology\" \/>\n<meta property=\"og:description\" content=\"Purpose &#x2014; The aim of the study was to assess the feasibility of an approach combining computational methods and pharmacoepidemiology to identify\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.ices.on.ca\/fr\/publications\/journal-articles\/identifying-drugs-with-disease%e2%80%90modifying-potential-in-parkinsons-disease-using-artificial-intelligence-and-pharmacoepidemiology\/\" \/>\n<meta property=\"og:site_name\" content=\"ICES\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/ICESOntario\/\" \/>\n<meta property=\"article:modified_time\" content=\"2023-06-14T23:42:16+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.ices.on.ca\/wp-content\/uploads\/2024\/11\/ic-es-data-discovery-better-health-logo.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" \/>\n\t<meta property=\"og:image:height\" content=\"675\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.ices.on.ca\\\/fr\\\/publications\\\/journal-articles\\\/identifying-drugs-with-disease%e2%80%90modifying-potential-in-parkinsons-disease-using-artificial-intelligence-and-pharmacoepidemiology\\\/\",\"url\":\"https:\\\/\\\/www.ices.on.ca\\\/fr\\\/publications\\\/journal-articles\\\/identifying-drugs-with-disease%e2%80%90modifying-potential-in-parkinsons-disease-using-artificial-intelligence-and-pharmacoepidemiology\\\/\",\"name\":\"ICES | Identifying drugs with disease\u2010modifying potential in Parkinson's disease using artificial intelligence and pharmacoepidemiology\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.ices.on.ca\\\/fr\\\/#website\"},\"datePublished\":\"2020-05-14T04:00:00+00:00\",\"dateModified\":\"2023-06-14T23:42:16+00:00\",\"description\":\"Purpose &#x2014; The aim of the study was to assess the feasibility of an approach combining computational methods and pharmacoepidemiology to identify\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.ices.on.ca\\\/fr\\\/publications\\\/journal-articles\\\/identifying-drugs-with-disease%e2%80%90modifying-potential-in-parkinsons-disease-using-artificial-intelligence-and-pharmacoepidemiology\\\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.ices.on.ca\\\/fr\\\/publications\\\/journal-articles\\\/identifying-drugs-with-disease%e2%80%90modifying-potential-in-parkinsons-disease-using-artificial-intelligence-and-pharmacoepidemiology\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.ices.on.ca\\\/fr\\\/publications\\\/journal-articles\\\/identifying-drugs-with-disease%e2%80%90modifying-potential-in-parkinsons-disease-using-artificial-intelligence-and-pharmacoepidemiology\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.ices.on.ca\\\/fr\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Journal Articles\",\"item\":\"https:\\\/\\\/www.ices.on.ca\\\/fr\\\/publications\\\/journal-articles\\\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Identifying drugs with disease\u2010modifying potential in Parkinson&#8217;s disease using artificial intelligence and pharmacoepidemiology\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.ices.on.ca\\\/fr\\\/#website\",\"url\":\"https:\\\/\\\/www.ices.on.ca\\\/fr\\\/\",\"name\":\"ICES\",\"description\":\"POPULATION-BASED HEALTH RESEARCH THAT MAKES A DIFFERENCE\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.ices.on.ca\\\/fr\\\/#organization\"},\"alternateName\":\"Institute for Clinical Evaluative Sciences\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.ices.on.ca\\\/fr\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.ices.on.ca\\\/fr\\\/#organization\",\"name\":\"ICES\",\"alternateName\":\"Institute for Clinical Evaluative Sciences\",\"url\":\"https:\\\/\\\/www.ices.on.ca\\\/fr\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/www.ices.on.ca\\\/fr\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/www.ices.on.ca\\\/wp-content\\\/uploads\\\/2023\\\/04\\\/ices-logo.png\",\"contentUrl\":\"https:\\\/\\\/www.ices.on.ca\\\/wp-content\\\/uploads\\\/2023\\\/04\\\/ices-logo.png\",\"width\":\"676\",\"height\":\"618\",\"caption\":\"ICES\"},\"image\":{\"@id\":\"https:\\\/\\\/www.ices.on.ca\\\/fr\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/ICESOntario\\\/\",\"https:\\\/\\\/www.linkedin.com\\\/company\\\/ices-research-institute\\\/\"]}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"ICES | Identifying drugs with disease\u2010modifying potential in Parkinson's disease using artificial intelligence and pharmacoepidemiology","description":"Purpose &#x2014; The aim of the study was to assess the feasibility of an approach combining computational methods and pharmacoepidemiology to identify","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.ices.on.ca\/fr\/publications\/journal-articles\/identifying-drugs-with-disease%e2%80%90modifying-potential-in-parkinsons-disease-using-artificial-intelligence-and-pharmacoepidemiology\/","og_locale":"fr_FR","og_type":"article","og_title":"ICES | Identifying drugs with disease\u2010modifying potential in Parkinson's disease using artificial intelligence and pharmacoepidemiology","og_description":"Purpose &#x2014; The aim of the study was to assess the feasibility of an approach combining computational methods and pharmacoepidemiology to identify","og_url":"https:\/\/www.ices.on.ca\/fr\/publications\/journal-articles\/identifying-drugs-with-disease%e2%80%90modifying-potential-in-parkinsons-disease-using-artificial-intelligence-and-pharmacoepidemiology\/","og_site_name":"ICES","article_publisher":"https:\/\/www.facebook.com\/ICESOntario\/","article_modified_time":"2023-06-14T23:42:16+00:00","og_image":[{"width":1200,"height":675,"url":"https:\/\/www.ices.on.ca\/wp-content\/uploads\/2024\/11\/ic-es-data-discovery-better-health-logo.jpg","type":"image\/jpeg"}],"twitter_card":"summary_large_image","schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.ices.on.ca\/fr\/publications\/journal-articles\/identifying-drugs-with-disease%e2%80%90modifying-potential-in-parkinsons-disease-using-artificial-intelligence-and-pharmacoepidemiology\/","url":"https:\/\/www.ices.on.ca\/fr\/publications\/journal-articles\/identifying-drugs-with-disease%e2%80%90modifying-potential-in-parkinsons-disease-using-artificial-intelligence-and-pharmacoepidemiology\/","name":"ICES | Identifying drugs with disease\u2010modifying potential in Parkinson's disease using artificial intelligence and pharmacoepidemiology","isPartOf":{"@id":"https:\/\/www.ices.on.ca\/fr\/#website"},"datePublished":"2020-05-14T04:00:00+00:00","dateModified":"2023-06-14T23:42:16+00:00","description":"Purpose &#x2014; The aim of the study was to assess the feasibility of an approach combining computational methods and pharmacoepidemiology to identify","breadcrumb":{"@id":"https:\/\/www.ices.on.ca\/fr\/publications\/journal-articles\/identifying-drugs-with-disease%e2%80%90modifying-potential-in-parkinsons-disease-using-artificial-intelligence-and-pharmacoepidemiology\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.ices.on.ca\/fr\/publications\/journal-articles\/identifying-drugs-with-disease%e2%80%90modifying-potential-in-parkinsons-disease-using-artificial-intelligence-and-pharmacoepidemiology\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.ices.on.ca\/fr\/publications\/journal-articles\/identifying-drugs-with-disease%e2%80%90modifying-potential-in-parkinsons-disease-using-artificial-intelligence-and-pharmacoepidemiology\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.ices.on.ca\/fr\/"},{"@type":"ListItem","position":2,"name":"Journal Articles","item":"https:\/\/www.ices.on.ca\/fr\/publications\/journal-articles\/"},{"@type":"ListItem","position":3,"name":"Identifying drugs with disease\u2010modifying potential in Parkinson&#8217;s disease using artificial intelligence and pharmacoepidemiology"}]},{"@type":"WebSite","@id":"https:\/\/www.ices.on.ca\/fr\/#website","url":"https:\/\/www.ices.on.ca\/fr\/","name":"ICES","description":"POPULATION-BASED HEALTH RESEARCH THAT MAKES A DIFFERENCE","publisher":{"@id":"https:\/\/www.ices.on.ca\/fr\/#organization"},"alternateName":"Institute for Clinical Evaluative Sciences","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.ices.on.ca\/fr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Organization","@id":"https:\/\/www.ices.on.ca\/fr\/#organization","name":"ICES","alternateName":"Institute for Clinical Evaluative Sciences","url":"https:\/\/www.ices.on.ca\/fr\/","logo":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/www.ices.on.ca\/fr\/#\/schema\/logo\/image\/","url":"https:\/\/www.ices.on.ca\/wp-content\/uploads\/2023\/04\/ices-logo.png","contentUrl":"https:\/\/www.ices.on.ca\/wp-content\/uploads\/2023\/04\/ices-logo.png","width":"676","height":"618","caption":"ICES"},"image":{"@id":"https:\/\/www.ices.on.ca\/fr\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/ICESOntario\/","https:\/\/www.linkedin.com\/company\/ices-research-institute\/"]}]}},"_links":{"self":[{"href":"https:\/\/www.ices.on.ca\/fr\/wp-json\/wp\/v2\/journal_article\/2933","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.ices.on.ca\/fr\/wp-json\/wp\/v2\/journal_article"}],"about":[{"href":"https:\/\/www.ices.on.ca\/fr\/wp-json\/wp\/v2\/types\/journal_article"}],"acf:post":[{"embeddable":true,"href":"https:\/\/www.ices.on.ca\/fr\/wp-json\/wp\/v2\/research_program\/6740"},{"embeddable":true,"href":"https:\/\/www.ices.on.ca\/fr\/wp-json\/wp\/v2\/site\/6733"},{"embeddable":true,"href":"https:\/\/www.ices.on.ca\/fr\/wp-json\/wp\/v2\/ices_scientist\/1108"},{"embeddable":true,"href":"https:\/\/www.ices.on.ca\/fr\/wp-json\/wp\/v2\/ices_scientist\/1159"},{"embeddable":true,"href":"https:\/\/www.ices.on.ca\/fr\/wp-json\/wp\/v2\/ices_scientist\/1328"}],"wp:attachment":[{"href":"https:\/\/www.ices.on.ca\/fr\/wp-json\/wp\/v2\/media?parent=2933"}],"wp:term":[{"taxonomy":"migration-helper-automated","embeddable":true,"href":"https:\/\/www.ices.on.ca\/fr\/wp-json\/wp\/v2\/migration-helper-automated?post=2933"},{"taxonomy":"migration-manual","embeddable":true,"href":"https:\/\/www.ices.on.ca\/fr\/wp-json\/wp\/v2\/migration-manual?post=2933"},{"taxonomy":"topic","embeddable":true,"href":"https:\/\/www.ices.on.ca\/fr\/wp-json\/wp\/v2\/topic?post=2933"},{"taxonomy":"migration-helper-qa-sample-set","embeddable":true,"href":"https:\/\/www.ices.on.ca\/fr\/wp-json\/wp\/v2\/migration-helper-qa-sample-set?post=2933"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}